GnRH-ant protocols with the advantages such as the shorter duration of the analog treatment, the shorter duration of stimulation with FSH and the lower risk of developing OHSS (48, 49), have been widely used in clinical practice since 2001, especially for normal and high ovarian responders (50, 51). Here, BRD2 is linked to ovarian hyperstimulation syndrome.